TrialDiabetes, obesity & metabolism2022

Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.

Yogesh Yadav et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.